ReviewFrontiers in psychiatry2013
Pathways from cannabis to psychosis: a review of the evidence.
Review in Frontiers in psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.BMC psychiatry · 2026Pooled it
- Cannabis use and psychosis: a review of reviews.European archives of psychiatry and clinical neuroscience · 2020Pooled it
- Mapping the Interplay Between Childhood Trauma, Substance Use, and Psychopathology in Early Psychosis: A Network Analysis Approach.Schizophrenia bulletin · 2026Article
- Remission with or without comorbid substance use disorders in early psychosis: long-term outcome in integrated care (ACCESS III study).Frontiers in psychology · 2023Article
- Portable Neuroimaging-Guided Noninvasive Brain Stimulation of the Cortico-Cerebello-Thalamo-Cortical Loop-Hypothesis and Theory in Cannabis Use Disorder.Brain sciences · 2022Article
- [Asthma and cannabis, cocaine or heroin use].Revue des maladies respiratoires · 2020Review
- Neighborhood-level predictors of age at onset and duration of untreated psychosis in first-episode psychotic disorders.Schizophrenia research · 2020Article
- Assessing the impacts of daily Cannabis versus alcohol and methamphetamines on young Australians in youth AOD treatment.BMC psychiatry · 2019Article
- Demographic and socioenvironmental predictors of premorbid marijuana use among patients with first-episode psychosis.Schizophrenia research · 2018Article
- The Effects of Cannabinoids on Executive Functions: Evidence from Cannabis and Synthetic Cannabinoids-A Systematic Review.Brain sciences · 2018Review
- Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective.Frontiers in public health · 2018Review
- Toward the Identification of a Specific Psychopathology of Substance Use Disorders.Frontiers in psychiatry · 2017Review
- Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia.Schizophrenia research · 2016Review
- Adverse effects of marijuana use.The Linacre quarterly · 2016Article
- Hippocampal cannabinoid transmission modulates dopamine neuron activity: impact on rewarding memory formation and social interaction.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Article
- A critical assessment of the equal-environment assumption of the twin method for schizophrenia.Frontiers in psychiatry · 2015Review
- mHealth App for Cannabis Users: Satisfaction and Perceived Usefulness.Frontiers in psychiatry · 2015Article
- Clearing the smokescreen: the current evidence on cannabis use.Frontiers in psychiatry · 2015Article
- Informed consent in the psychosis prodrome: ethical, procedural and cultural considerations.Philosophy, ethics, and humanities in medicine : PEHM · 2014Review
- Neuronal substrates and functional consequences of prenatal cannabis exposure.European child & adolescent psychiatry · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nature of the relationship between cannabis use (CU) and psychosis is complex and remains unclear. Researchers and clinicians remain divided regarding key issues such as whether or not cannabis is an independent cause of psychosis and schizophrenia. This paper reviews the field in detail, examining questions of causality, the neurobiological basis for such causality and for differential inter-individual risk, the clinical and cognitive features of psychosis in cannabis users, and patterns of course and outcome of psychosis in the context of CU. The author proposes two major pathways from cannabis to psychosis based on a differentiation between early-initiated lifelong CU and a scenario where vulnerable individuals without a lifelong pattern of use consume cannabis over a relatively brief period of time just prior to psychosis onset. Additional key factors determining the clinical and neurobiological manifestation of psychosis as well as course and outcome in cannabis users include: underlying genetic and developmental vulnerability to schizophrenia-spectrum disorders; and whether or not CU ceases or continues after the onset of psychosis. Finally, methodological guidelines are presented for future research aimed at both elucidating the pathways that lead from cannabis to psychosis and clarifying the long-term outcome of the disorder in those who have a history of using cannabis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.